Intra-Cellular Therapies Inc reports results for the quarter ended in September - Earnings Summary

Intra-Cellular Therapies

02/11/2023 15:44

* Intra-Cellular Therapies Inc  ITCI.OQ  reported a
quarterly
adjusted loss of 25 cents​​ per share for the quarter ended in
September, higher than the same quarter last year, when the
company reported EPS of -57 cents.  The mean expectation of
thirteen analysts for the quarter was for a loss of 57 cents per
share. Wall Street expected results to range from -67 cents
to -46 cents per share.
    * Revenue rose 75.6% to $126.17 million from a year ago;
analysts
expected $119.23 million. 
    * Intra-Cellular Therapies Inc's reported EPS for the
quarter was
a loss of 25 cents​.
    * The company reported a quarterly loss of $24.26 million.
    * Intra-Cellular Therapies Inc shares had fallen by 2.3%
this
quarter and lost 3.9% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 2.3%
in the last three months.​ 
    * In the last 30 days, five analysts negatively revised
earnings
estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 12 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"

Wall Street's median 12-month price target for Intra-Cellular
Therapies Inc is $76.00 
This summary was machine generated from LSEG data November 2 at
03:44 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2023      -0.57          -0.25          Beat
 Jun. 30 2023      -0.59          -0.45          Beat
 Mar. 31 2023      -0.61          -0.46          Beat
 Dec. 31 2022      -0.59          -0.45          Beat